Special Issue "Mesenchymal-Stem-Cell-Based Drug Delivery Strategies for Biomedical Applications"
Deadline for manuscript submissions: 25 March 2024 | Viewed by 207
Interests: molecular mechanisms; cell therapy; mesenchymal stem cells; tissue regeneration; drug delivery; epithelial-to-mesenchymal transition; microRNA; molecular cancer biology; metastasis; personalized medicine
Interests: somatic cell reprogramming; gene/cell therapy; mesenchymal stem cells; induced pluripotent stem cells; molecular mechanisms; targeted delivery; chemical carriers; personalized medicine
Targeted delivery of drugs to specific organs and tissues is one of the most important directions in translational and clinical research. Among various drug-targeting approaches, cell-based delivery systems offer some unique strengths and have achieved exciting preclinical and clinical results. The use of mesenchymal stem cells as a targeted-delivery carrier is promising due to their ease of isolation, expansion, maintenance of their phenotype, and multilineage potential in vitro. Currently, MSC-based delivery represents a promising approach for several clinical applications, ranging from tissue repair to the treatment of pathologies such as diabetes, cardiovascular disease, neurological disorders, and cancer.
However, this approach still has many limitations in clinical translation, such as induction of immunogenicity, high costs, or variable effects. Moreover, the long-term effect of priming MSCs has not been evaluated yet. Further studies are needed to assess the impact of different priming approaches in clinic; the best sources for MSCs isolation; and the epigenetic modifications, immunogenicity, and tumorigenicity of primed and non-primed MSCs.
This Special Issue aims to present a collection of high-quality original articles and extensive reviews on MSC-based drug delivery systems for various clinical applications. Colleagues and authors are invited to submit papers that fall within the scope of this Special Issue.
Dr. Karolina Bajdak-Rusinek
Dr. Agnieszka Fus-Kujawa
Prof. Dr. Paweł Buszman
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- mesenchymal stem cell
- cell-based therapy
- drug delivery system
- cell migration
- MSC priming
- biomedical applications